CIA
AXDX

Cladis Investment Advisory’s Accelerate Diagnostics AXDX Stock Holding History

Cladis Investment Advisory’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,700
Closed -$29.9K – 148
2025
Q1 		$29.9K Hold
42,700
– – 0.02% 136
2024
Q4 		$51.2K Buy
42,700
+3,000
+8% +$4.98K 0.04% 129
2024
Q3 		$67.9K Hold
39,700
– – 0.05% 133
2024
Q2 		$46.4K Buy
+39,700
New +$41.5K 0.03% 134
2024
Q1 		– Sell
-31,700
Closed -$124K – 140
2023
Q4 		$124K Sell
31,700
-4,450
-12% -$23.5K 0.1% 135
2023
Q3 		$208K Sell
36,150
-1,100
-3% -$7.4K 0.18% 119
2023
Q2 		$302K Sell
37,250
-10,000
-21% -$75.1K 0.26% 102
2023
Q1 		$331K Buy
47,250
+3,550
+8% +$21.3K 0.3% 95
2022
Q4 		$309K Sell
43,700
-10,350
-19% -$113K 0.31% 94
2022
Q3 		$822K Sell
54,050
-8,300
-13% -$137K 0.89% 36
2022
Q2 		$619K Sell
62,350
-3,190
-5% -$28.2K 0.62% 55
2022
Q1 		$944K Buy
65,540
+19,450
+42% +$554K 0.76% 40
2021
Q4 		$2.41M Buy
+46,090
New +$2.57M 1.93% 7

Other funds holding AXDX

BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Cladis Investment Advisory's AXDX Position: Q2 2025 in Review

Cladis Investment Advisory sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 42,700 shares — an estimated $29.9K sold.

Cladis Investment Advisory first reported a position in AXDX in Q4 2021 and held it in 13 quarters. The position peaked at $2.41M in Q4 2021. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

  • Cladis Investment Advisory reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Cladis Investment Advisory sold 42,700 Accelerate Diagnostics shares in Q2 2025, an estimated $29.9K.
  • Cladis Investment Advisory first reported a position in Accelerate Diagnostics in Q4 2021 and held it in 13 quarters.
  • Cladis Investment Advisory's Accelerate Diagnostics position peaked at $2.41M in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Cladis Investment Advisory's 13F filing for Q2 2025, filed 11 Aug 2025.